ODDITY reports robust growth, eyes future innovation By Investing.com

ODDITY (Ticker: ODD), a leader in the beauty and wellness industry, has announced a record-breaking financial performance for the fourth quarter and full year of 2023, with $509 million in net revenue and over $100 million in adjusted EBITDA.

The company’s focus on online and science-driven innovation, including the development of ODDITY LABS for molecule discovery, has positioned it for continued growth. With the IL MAKIAGE and SpoiledChild brands driving sales, ODDITY aims to reach $1 billion in revenue for each brand and lead in industry innovation. The company also plans to launch multiple new products from ODDITY LABS and expects a net revenue growth of 22-24% for 2024.

Key Takeaways

• ODDITY surpassed $500 million in revenue in 2023, with significant contributions from its IL MAKIAGE and SpoiledChild brands.
• The company’s online platform boasts over 50 million users and 2 billion data points.
• Skin products accounted for 20% of IL MAKIAGE sales, while SpoiledChild achieved $110 million in net revenue.
• ODDITY LABS, with its proprietary molecule Fibroquin, is set to revolutionize the beauty industry.
• The company forecasts a net revenue growth of 22-24% and an adjusted EBITDA between $136 million and $140 million for 2024.
• Investments in technology and new brands will be concentrated in the last nine months of the year.

Company Outlook

• ODDITY expects to maintain a gross margin of 70.5%.
• Anticipated adjusted diluted earnings per share for the full year are between $1.49 and $1.54.
• The company plans to invest heavily in growth initiatives, particularly in ODDITY LABS and new brand launches.

Bearish Highlights

• Marketing expenses are projected to grow in line with sales in 2024.
• The launch of new brands may temporarily impact profit margins.

Bullish Highlights

• SpoiledChild’s rapid scaling and IL MAKIAGE’s growth contribute to a strong financial outlook.
• ODDITY LABS and vision technology are expected to be high-impact revenue drivers.
• The company is set to continue growth in North America and international markets.

Misses

• There were no specific financial misses mentioned in the earnings call summary.

Q&A Highlights

• The company’s land-and-expand model is anticipated to yield high returns on investment.
• Brand 3 will offer OTC and prescription options through third-party pharmacies.
• Brand 4 is in development, with future updates to be provided.

ODDITY’s earnings call underscored its commitment to innovation and growth. With a strong financial foundation and a strategic focus on technology-driven product development, ODDITY is poised to continue its trajectory of robust growth and industry leadership. The company’s ambitious goals, backed by its innovative ODDITY LABS and expansion into new brands and markets, signal a forward-thinking approach that could redefine the beauty and wellness space. Investors and industry watchers will be closely monitoring ODDITY’s progress as it works to achieve its vision for science-backed beauty solutions and online platform expansion.

InvestingPro Insights

ODDITY’s impressive financial performance is further illuminated by real-time data that underscores the company’s strong market position and potential for future growth. Here are some key metrics and InvestingPro Tips that investors might consider:

InvestingPro Data:

• Market Capitalization: As of the last update, ODDITY’s market cap stands at $2.49 billion USD, reflecting significant investor confidence in the company’s value and future prospects.

• Revenue Growth: The company has experienced a remarkable revenue growth of 56.75% over the last twelve months as of Q4 2023, highlighting its successful expansion and market penetration strategies.

• Gross Profit Margin: ODDITY maintains a robust gross profit margin of 70.42%, which suggests efficient management and a strong pricing strategy.

InvestingPro Tips:

• Analysts are optimistic about ODDITY’s sales growth in the current year, which aligns with the company’s own revenue growth projections of 22-24% for 2024.

• With three analysts revising their earnings upwards for the upcoming period, there is a consensus belief in ODDITY’s continued financial success, particularly in light of its innovative product launches and market expansion plans.

Additional insights and InvestingPro Tips are available, and investors looking to delve deeper into ODDITY’s financial health and future outlook can explore further on InvestingPro. To enhance your research experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With a total of 14 InvestingPro Tips listed for ODDITY, investors have an abundance of valuable information at their fingertips.

Full transcript – Oddity Tech (ODD) Q4 2023:

Operator: Good morning. And welcome to ODDITY’s Fourth Quarter and Full Year 2023 Earnings Conference Call. Today’s call is being recorded and we have allocated time for prepared remarks and Q&A. Please note the prepared remarks for this morning’s call have been posted to ODDITY’s Investor Relations website for reference. At this time, I’d like to turn the conference over to Maria Lycouris, Investor Relations for ODDITY. Thank you. You may begin.

Maria Lycouris: Thank you, Operator. I’m joined by Oran Holtzman, ODDITY Co-Founder and CEO; Dr. Evan Zhao, ODDITY’s Chief Science Officer; and Lindsay (NYSE:) Drucker Mann, ODDITY’s Global CFO. As a reminder, management’s remarks on this call that do not concern past events are forward-looking statements. These may include predictions, expectations or estimates, including statements about ODDITY’s business strategy, market opportunity, future financial performance and potential long-term success. Forward-looking statements involve risks and uncertainties and actual results could differ materially due to a variety of factors. These factors are described under forward-looking statements in our earnings press release issued yesterday and in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 5, 2024. We do not undertake any obligation to update forward-looking statements which speak only as of today. Finally, during this call we will discuss certain non-GAAP financial measures, which we believe are useful, supplemental measures for understanding the business. Additional information about these non-GAAP financial measures, including their definitions, are included in our earnings press release, which we issued yesterday. I will now hand the call over to Oran.

Oran Holtzman: Thanks, Operator, and thanks everyone for joining us today. Our fourth quarter was another record-breaking quarter to cap off a record year. We continue to deliver very strong financial results that are ahead of what we promised. In 2023 we reached two important milestones; one, surpassing $500 million of revenue; and two, generating over $100 million of adjusted EBITDA. We did it via our online platform that was launched only five years ago in a category that everyone told me doesn’t and cannot work online. The ODDITY platform has today over 50 million users and over 2 billion data points that fuel our business and are responsible for the strong financial results. Our financial results for 2023 were outstanding. We grew net revenue 57% to $509 million and adjusted EBITDA 173% to $107 million, achieving 21% adjusted EBITDA margins. Once again beating our guidance across revenue, profit and earnings per share. Not just for the full year, but every single quarter. We basically grew way more than I wanted us to grow. In my view, there is no good reason to grow 50% at our scale, but due to both SpoiledChild’s ability to blitzscale and IL MAKIAGE’s stronger than expected repeat rate, we landed at a 57% growth rate in 2023 full year. Drilling down to the brands. IL MAKIAGE delivered a very strong year in both color and skin. Skin grew to around 20% of IL MAKIAGE’s sales in 2023, which is very high rate of category expansion for any beauty brand. It is a testament to our data-driven platform, to the strength of the brand, its enormous potential reach and the quality of its products. IL MAKIAGE is well on its way to achieving my target of $1 billion of sales within the next five years. SpoiledChild scaled insanely fast in 2023. Since it was a one-year-old brand, I wanted to test the brand strength and its limits, and therefore, I allowed the hyper growth. SpoiledChild grew 325% from last year to $110 million of net revenue and we did it profitably, across multiple categories and with more than half of our sales from repeat customers. We believe SpoiledChild’s success is unprecedented anywhere in direct-to-consumer and it just showed again the strength of ODDITY and the demand for beauty online. Most importantly for 2023, we built strong foundations to drive our future. The Revela acquisition and establishment of ODDITY LABS is a game changer for the industry. We are all in in building the biggest and most advanced platform for new molecule discovery. I believe it will be a huge growth engine for all our brands and therefore it is a top priority and focus for me and for my sister, Shiran. But I’ll touch it more shortly. New brands are another massive growth engine for us, where we made big investments in Brand 3 and Brand 4, which are on track to be launched in 2025. Finally, we took ODDITY public. Again, we did it to build something huge, and because we believe there is unlimited growth potential for us. So to recap, 2023 was a very strong year for ODDITY. We delivered 57% growth and 21% EBITDA margin, top percentile of public companies out there. We beat every quarter of 2023 with scale, growth and profitability. We crossed the $500 million milestone of net revenue. We crossed the $100 million milestone of adjusted EBITDA. We established ODDITY LABS as an industry leading molecule discovery platform, powered by the acquisition and integration of Revela. We took the company public with an amazing shareholder base and we finished the year with a very strong balance sheet, including $168 million of cash and short-term investments with zero debt. This is ODDITY, we work really hard to do more than most other companies out there. The hunger, the startup DNA and our always-on competitive mode are our biggest assets that allow us to keep on delivering. So 2023 was amazing, but it’s already the past and what’s most important now is our future. Our laser focus in 2024 is on executing opportunities that we believe will drive our business for many years. Let me walk you through the biggest priorities for our team in 2024. First, continuing to grow IL MAKIAGE and SpoiledChild. As I said before, our goal for both brands is to grow to $1 billion revenues for each brand. With strong separated leadership team for each brand, with a huge addressable market, with massive advantage online where the demand is only growing, it can and should be done. So many ways to grow, adding new products, expanding to new categories, opening up new markets. All growth initiatives are in place and ready for pulling the trigger, so I feel very confident in the ability of my teams to deliver. Both IL MAKAIGE and SpoiledChild are off to a strong start in 2024. Based on our performance in just the first two months of 2024, combined with our outlier repeat rates, we have visibility into delivering our goals for 2024. So that was about SpoiledChild and IL MAKIAGE. Second, new brands. Brand 3 and Brand 4, which we are building to be our next in-house engines. Both brands have separated leadership teams to ensure they win without distracting the existing brands runway. As a reminder, Brand 3 is a medical grade skin and body brand. Issues like acne, eczema and other skin issues are huge pain points for our users and the majority of them tell us they are unsatisfied with the current solutions. The user experience is bad and the products on the market don’t work well. With Brand 3, we are building end-to-end solutions that position us to win. This includes a first of its kind mobile platform that uses data, AI and computer vision to deliver a diagnosis, a precise treatment protocol and coaching to ensure the user compliance and success. It also leverages ODDITY LABS to develop high performing products from our proprietary molecules that truly solve consumer skin issues and concerns. Brand 4 we have not yet announced the category, but we are confident in its ability to grow very fast. Last, but top priority and potential is ODDITY LABS. What we are building LABS is full disruption. If we do it right, ODDITY LABS will change our industry and our company. The potential is unlike anything that I saw in the industry, even more than unlocking online five years ago. With my focus, our speed as a company, and ODDITY LABS talent we have a first mover advantage and we will see the results in two years, three years from now. Big bet but huge swing. To summarize, I remain very bullish about what we are building here at ODDITY. Beauty and wellness is one of the most attractive markets in the world. Huge, growing, profitable, with so many categories to drive our business. At the same time, the market is held back by legacy models that are completely stuck in the past. I see two unstoppable pillars of transformation in our industry and we have positioned ODDITY far ahead in order to win in both. The first pillar is the consumer is moving online. I believe online will be the largest channel in the category at 50% or more. And we made massive investments in technology, in data, in AI and in computer vision in the past six years to ensure we have what we need in order to win. This muscle is what allows us to lead online and build a portfolio of large DTC brands with very strong financial profiles. So the shift to online is the first unstoppable trend I see and we are already leading on this front. The second pillar of transformation in our industry is the shift towards science-backed products. The consumer today is smarter than ever. We can see it in how they engage in our platform, the amount of time they spend reading about our products and how much they care about our ingredients. Although pharma and biotech had insane progress in the past two decades, the beauty industry, even us, have fallen short, remixing old ingredients in new packaging. This creates an incredible opportunity and this is what we are doing with ODDITY LABS, using digital biology to discover and own the next-generation of science-backed category killers that consumers love. What we are doing with LABS in Boston is the same as what we did with our R&D center in Tel Aviv. But this time instead of transforming experience, we are transforming the products themselves and I believe it will be huge. So, with that, let me hand the call over to Dr. Evan Zhao, our Chief Science Officer, to dive deeper into what we are building at LABS.

Dr. Evan Zhao: Thanks, Oran. I’m Dr. Evan Zhao, Chief Science Officer of ODDITY and I lead the team at ODDITY LABS. I joined ODDITY with the acquisition of Revela, which is a biotech that my co-founders and I started while doing research at Harvard. At the time, we were pioneering digital biology for therapeutic development at the Wyss Institute. We saw what we thought was a once in a generation opportunity, to close a huge technology gap, really a gaping deficiency of science in the beauty and wellness industry. We are living in the golden age of science, where new technology has allowed pharma and biotech to innovate at an unprecedented pace. Yet, the beauty and wellness industry is still living in the dark ages. No molecule innovation, totally commoditized, just old ingredients repackaged and not addressing consumer problems. It doesn’t make sense given the size of the beauty industry, a huge TAM with zero real science. So this is the massive opportunity we are running at with LABS. Unleashing the full power of technology and digital biology to discover ground-breaking ingredients that really perform, that really solve consumer pain points and can power the next generation of category killers. This is what consumers want. Based on data we see in ODDITY’s massive user base, the consumer is way smarter than before, cares less about brands and more about efficacy. But we are still in early days, the shift will be enormous over the next decade. Few words about the field so it will be easier to understand what we do at ODDITY LABS. Digital biology is the marriage of breakthrough technologies, including AI and synthetic biology. It is widely used across pharma today, but not in our industry. And these technologies allow us to do three things there were never before possible; one, measure data at scale; two, analyze massive data sets at scale; and three, bioengineer solutions based on this data. The discovery process in digital biology is revolutionary when compared to the status quo. The status quo today is basically the same ancient approach used with Chinese herbal medicine of trial and error. Let me give you an example, starting with skin aging. The dominant solution for skin tightness on the market for decades has been retinol. Retinol’s discovery was an accident. It was originally used to treat blindness, but like so many solutions in our industry, it was meant for something else and repurposed for skin. Along the way, scientists optimize using chemistry and formulations to make it the best skin tightening solution it could be. Which, by the way, is not a great one. Which means we are left with an ingredient, that doesn’t work that well, that has all kinds of side effects and is a bad user experience because it causes skin peeling and purging. That you can’t even use if you’re pregnant. This is what consumers have to settle for. So let’s compare that discovery process with how we did it at ODDITY LABS and how we discovered Fibroquin, our proprietary skin health molecule, which despite being in V1, already outperforms retinol with stronger efficacy, making skin tighter and bouncier and higher user satisfaction. Instead of trial and error, we start with the skin itself. We make biological models which are essentially pieces of skin in a dish, modified so they can give us measurable data. We take thousands of these pieces of skin and then expose them each to thousands of different molecules, and we measure and track how each skin piece interacts with each individual molecule. We then feed that information into an AI that simulates how that same skin would interact with, not a thousand molecules, but with a billion different molecules. We then identify dozens of that make the skin better, and from these dozens of hits, we test for things like toxicity, efficacy, safety and specificity until we find the absolute winner. The difference in these two approaches, the industry standard trial and error approach versus our digital biology discovery platform is revolutionary. We are catalyzing a pace of discovery and innovation that our industry has never seen. With massive benefits for consumers. Fibroquin not only is twice as good as retinol in double blind clinical trials for increasing skin elasticity, it is also substantially safer than retinol in every single test we’ve run, including how if effects other cells in the body and actually mimicking long term effects. Plugging into ODDITY’s massive user platform allows us, for the first time, to bring consumers in as our design partners. We have a direct dialogue to understand not just their pain points, but also how they want the product to work, what the form factor should be, what attributes matter in the formulation in order to make for the best user experience. Over the last year since joining forces with ODDITY, we have dramatically scaled our capabilities. We are growing a super elite team of PhDs and scientists from top institutions, who are empowered by our entrepreneurial culture and the chance to see their ideas make real change for tens of millions of consumers around the globe. We have massively expanded our roadmap to address huge market opportunities. We believe we can dominate in hair. We believe we can dominate in skin, face and body. We believe we can create a next-generation of high-performance cosmetics and this is just the beginning. We are making big investments in our team, in our LAB, in our product development capabilities, in our tech and in extensive focus groups and trials, in order to support this effort. In two years to three years you will see real science-backed products for full disruption to take massive market share. And with that, I’ll hand over to Lindsay.

Lindsay Drucker Mann: Thanks, Evan. Let’s turn to our 2023 results which I will refer to on an adjusted basis. You can find the full reconciliation to GAAP in our press release. ODDITY delivered a record-breaking year on all accounts. We grew net revenue by 57% to $509 million. This strength was driven by both IL MAKIAGE and SpoiledChild across a wide range of product categories. We grew net revenue 44% in the fourth quarter driven similarly by growth across products and brands. For the full year, revenue growth was driven mostly by increased orders, although we continue to see improvements in average order value driven by order size and product mix. More than half of ODDITY full year revenue was driven by repeat sales, which is remarkable when considering our scale and the speed at which we’re growing. Our revenue mix continues to evolve with the addition of new brands, categories and products. In 2023, new categories like skin and hair increased materially as a percentage of our overall revenue mix and we continued to see excellent growth and have enormous runway in color, even as we push to scale new categories at a faster pace. Expansion into new products and categories makes us even stronger. It allows us to understand our users better. We now know not just their makeup routines, but also we have a holistic skin, hair, makeup and wellness 360-degree view. We are gaining share of user wallets and doing it for very attractive incremental costs. This allows our financial model to deliver the kind of outsized returns you see in other land-and-expand models like software. In addition, we are bringing new users and converting new customers, who are now finding the products they want but couldn’t before get them from our brands. It is a flywheel that is accelerating as our platform grows, our users grow, our data capabilities and technology grows, brand awareness grows and brand love grows. We are seeing this benefit in increasing basket size, higher average order value and further improving repeat, and of course, it increases the surface area and extends our runway for growth. IL MAKIAGE delivered double-digit profitable growth in 2023 across cosmetics and skin. And as Oran mentioned, IL MAKIAGE Skin is now 20% of the brand sales. SpoiledChild came in at $110 million of net revenue, ahead of our expectation of $100 million of net revenue for the year, increasing more than 4x from 2023 and doing it profitably with more than 50% of sales coming from repeat customers. It’s an incredible accomplishment for a brand growing so quickly and less than two years old. Gross margin expanded 320 basis points for the year and 400 basis points for the quarter. This better-than-expected gross margin expansion was driven by specific supply-chain and logistics efficiency initiatives at both brands. Adjusted operating expense grew 42% for the full year, slower than sales growth of 57%. We were able to nicely leverage operating expense despite stepping up investment in future growth drivers like ODDITY LABS and new brands, due in large part to the higher proportion of repeat sales in our overall revenue mix, which are more profitable. We also made investments to drive increased business efficiency. We expanded our use of generative AI across multiple consumer touch points, including advertising, user experience and customer service. We are still very early in implementation here, but are seeing improvements across the P&L, from better conversion to operating cost efficiencies and we have not yet implemented generative AI to support coding and development, which we believe will save costs and drive efficiencies in the future. We delivered adjusted EBITDA of $107 million for the full year and $16 million for the quarter. Full year adjusted EBITDA margins of 21% expanded 900 basis points from the prior year, driven by gross margin expansion and higher mix of repeat, offset by increased investment in future growth drivers. We delivered adjusted diluted earnings per share of $1.31 for the full year and $0.17 for the quarter and reported diluted earnings per share of $1 and $0.08 for the same periods, respectively. Our asset light model and strong returns on capital once again supported very strong cash generation. We delivered $85 million of free cash flow in 2023 and we exited the year with $168 million of cash, equivalents and short-term investments on our balance sheet, and zero debt. And we strengthened our capital position early this year with $100 million credit facility that we can use for general corporate purposes, buybacks, acquisitions and other uses. Turning to our outlook. We remain committed to our long-term targets of 20%-plus revenue growth at a 20% adjusted EBITDA margin. To reiterate the purpose of our 20/20 strategy. For revenue growth, 20% is 2 times to 3 times faster than what legacy competitors are growing. As for 20% margin, the business is more profitable on an underlying basis, but in our view, there is no reason to deliver more than 20%. We are here to build something huge, therefore every excess dollar of margin we have, we invest in big bets that can change the industry and support our long-term growth. And in fact this has already proven to be an excellent use of our capital. Our track record of reinvestment is very strong, not just because our business already generates high returns on invested capital, but more specifically recall that we launched SpoiledChild with around $20 million of up-front investment, and as Oran said, we expect SpoiledChild will be a $1 billion brand. In 2024 specifically, based on our very strong start to the year, we expect to do even better than these long-term targets. We expect net revenue will increase between 22% to 24% for the year, driven by robust growth at both brands. In terms of pacing revenue, we plan to deliver relatively consistent low-to-mid 20s year-over-year growth every quarter across 2024. Turning to profitability, we expect to deliver 70.5% gross margin for the full year and we expect to deliver adjusted EBITDA for the year between $136 million and $140 million, which will include a step-up in growth investments, including LABS and new brands. The timing of these growth investments is skewed to the last nine months of the year, with limited impact on the first quarter. We expect adjusted diluted earnings per share will be between $1.49 to $1.54 for the full year 2024. Turning to the first quarter. As we discussed last year, we deliberately slowed the business down in the back half of 2023 in order to pace our growth, while our teams focused on huge preparations for 2024. We entered January with incredible strength and delivered a large acceleration in the business, more than doubling the Q4 pace and doing it very profitably. We quickly began to pace our sales ahead of plan, which, because of our strong repeat, already puts us in a position to secure our full year objectives and also leaves us the flexibility to once again begin holding our revenue growth back to leave more room for the future. The muscle and control our teams have to flex the business with precision is a huge strength for us and something really unique to ODDITY. Given the very strong start to the year, we expect Q1 net sales growth between 23% and 25%. You can find more details on our Q1 outlook in our press release. And with that, Operator, we are ready to take questions.

Operator: Thank you. [Operator Instructions] Thank you. Our first question comes from the line of Lorraine Hutchinson with Bank of America. Please proceed with your question.

Lorraine Hutchinson: Thank you. Good morning, everyone. I wanted to ask about some of the newness that you were planning to roll out this year. I think you had talked about 10 new molecules or products. How many of those are out there already and is there any initial commentary on how those are performing?

Oran Holtzman: Hi. Thanks for the question. So I think that you’re referring to LABS. In general, just for better understanding, each brand, aside from LAB, each brand has its own NPD department and they work constantly on developing new products and new categories for the existing brands. So they have way more than 10 products launching this year. Aside from that, we have what we have built in LABS, which are new molecules that we are starting to call. LABS and — in the development-wise on track and will be ready for this year. It doesn’t mean we launch them this year. We always have engines we keep ready to be launched based on revenue growth needs. If we see that we need more revenue power, then we launch them. This was always my approach with products, with categories and with other growth engines. Two or three products are going to be launched shortly. And again, we launch them, we test, we see their satisfaction and then we go back and decide at what scale we want to see from this product in the quarter or for the rest of the year. So, yes, all the 10 products will be ready to be launched. If we launch them, it’s up to us.

Lorraine Hutchinson: Okay and thank you. Lindsay, I wanted to clarify a point that you made, talking about entering January with incredible strength. I think you said you doubled the 4Q pace. So can you square that commentary with the revenue guidance, which implies slower growth than that? I guess, how much did you pull back on acquisition spending, and yeah, any other color you could give on the rest of the quarter after that strong start to January?

Lindsay Drucker Mann: Sure. Happy too. So I think one important differentiator between our model and many of the sort of legacy consumer models or beauty models that you’re familiar with is this sort of requirement as having stores or being brick-and-mortar to have a constant flow of inventory onto the shelves, which is really matched up to where customer traffic and demand is. For us, because we’re direct-to-consumer and because we have full control over our pace of acquisition, we set that pace, we pulse that spend. And so what you’ve seen us do in the past is come out really swinging in the first quarter and then significantly dialing down and really shutting off all new user acquisition into the back half of the year and that’s why our first half has been so front loaded relative to our second half. It’s not because beauty is big in the first quarter. In fact, the opposite if you look at all of our competitors, it’s the opposite, 4Q is the biggest. And so for us to, what I was referring to is in the third quarter we delivered $97 million of, sorry, in the fourth quarter, $97 million of net revenue and what our 1Q guidance is, we’re significantly, we basically on a dime turned the business back on, which is not easy to do, and again, something that we have particular strength. And so that we really, really ramped up and we saw demand explode, which was amazing. We had been preparing for it and expected it, but it’s always fun to watch the business really rip. And we were so pleased with, Jan and Feb, and what we’ve seen in early March, because of all the repeat in our business, we have very high visibility into achieving our full year objective now. It’s basically, 2024 is basically in the bag, which is great. And so I wouldn’t — I’m not — yeah, I think, you may be referring to the year-over-year growth rates, which is not the right way to think about it, since we’re really managing this in terms of demand pulse, so we increased 44% on a year-over-year basis for Q4. It’s a much smaller quarter for us that’s almost entirely repeat sales for us in Q4 and now we really turned the business on, and we’re managing to try to get much closer to that kind of, our 20% long-term target for 2024, although we’re slightly ahead of that at 2022 to 2024, that’s the type of growth rate we think is appropriate for the business to sustain and we plan to deliver in that range every quarter of this year.

Oran Holtzman: I would just add one more thing that, again, in Q1, the beginning of every Q1, we start again opening user acquisition and despite the high scale that we had in the past two months, we have seen an improvement in our marketing efficiency KPIs in terms of ROAS in Q1 of 2024 compared to 2023. So, though we, like, we pushed and we started again, and to acquire new users, the results are very strong and we don’t do it just because we need, we do it when the market allows and we’ve seen massive demand out.

Lorraine Hutchinson: Thank you.

Operator: Our next question comes from the line of Scott Schoenhaus with KeyBanc Capital Markets. Please proceed with your question.

Scott Schoenhaus: Hi, team. Thanks for taking my question. I wanted to focus on ODDITY LABS and the expansion of team and the expansion of scope in the projects that you mentioned that was in the release. Are these expansions more related to products within current brands, IL MAKIAGE, SpoiledChild? Are they for the new Brand 3 launch related to acute skin and Brand 4? Just kind of understanding where these investments, accelerated investments are going to? Thanks.

Oran Holtzman: Hi. So it’s important to understand for IL MAKIAGE and SpoiledChild, a lot of the work that is being done through LABS now is for Brand 3 [ph], which is a medical skin and body, which we are planning to launch many products from LABS for Brand 3. And in overall, LABS, is built in full power, and as a reminder, like what we do there is exactly, as Evan mentioned, [Technical Difficulty] and I am absolutely number one focus now. I’m literally trying to bust today after we finish the call. In terms of investment, we say investment is about people and I want to double the PhDs, the number of PhDs that we have done this year. We are now around 30 people and the target is to be more than 60 people by end of the year. We are putting a lot of investment in LABS today, both people in the way that in protocol, in building the LAB to make sure that we have enough, that the pipeline will be efficient for both end users. And we will have products ready this year to be launched and [Technical Difficulty] more case impacts, so development-wise everything has to be built. And by the way, like any other growth engine that we build, it doesn’t mean that we launch them as we did before. We always keep engines ready to be launched based on where they are needed. So if we see that I need more power, I already have a few products out there ready to be launched within IL MAKIAGE and SpoiledChild both coming from the LAB, but it’s going to be our decision. And [Technical Difficulty] Every product that we are working on takes time. It’s a long and deep process, and it takes around two years to develop a product in this LAB from idea to molecule discovery, all the way through incorporation into the high-efficiency product that exists in the market. We are using the best molecule discovery methods for bioengineering, synthetic biology, computational chemistry and artificial intelligence, and it starts all the way from the idea, from where we see in the user base, we see a segment that is craving for something better. Then we go back to LAB, we ask them if something can be done to create something better in terms of efficacy and then we start developing it and do that and use the power of LABS. So, again, multiple projects, more than 20 projects that LABS are now working on and not all of them will be successful, but we don’t need all of them, because each and every one of them can be a category killer.

Scott Schoenhaus: Thanks, Oren. And just a follow-up there. Can you remind us, on average, how long it takes from the initial idea and molecule discovery through any kind of regulatory process and then full commercialization on the molecule side? Thanks.

Oran Holtzman: Sure. So it’s around two years and I can give a bit more background, so maybe it’s going to help you understand what we do in LABS for the future. It starts by developing advanced biological models for specific use of pain points, replicating the underlying cause in a cell-based assay and evaluating specific physiological cell response. We then use a computational screening to search for molecules that will drive the desired cell response. We use deep learning models to predict which molecules have the highest chances of working with our target and we then perform a series of in-vehicle cell enzyme-based assays to provide that computational predictive molecule and then we go to safety. And then all identified cell molecules are evaluated in human trials to ensure our findings in LAB transfer to results on the people and outperform all existing authorities in the market and we have — that’s the way that we do it. It sometimes takes 18 months. It can take two and a half years. But in average, it’s two years from the moment that we task — we give them the task and to — and go-to-market.

Scott Schoenhaus: Thank you.

Operator: Our next question comes from the line of Youssef Squali with Truist Securities. Please proceed with your question.

Youssef Squali: Great. Thank you very much. Lindsay, can you help us think through your market expense cadence in 2024, overall and across both brands? And then Oren, SpoiledChild at $110 million in its first calendar year is really impressive and I believe it’s actually tracking ahead of where IL MAKIAGE was back in 2019. It was launched in 2018, I think. So do you think that kind of ramp for SpoiledChild in particular can continue at a kind of a faster rate than what you’ve seen with IL MAKIAGE, considering the much more developed platform now that you’re running? Thank you both.

Lindsay Drucker Mann: Okay. I’ll start with the marketing question. So we have market — we started the year with a significant ramp up in our acquisition spend — our user acquisition spend versus the fourth quarter and generated very, very effective returns on that marketing spend. And as Oren said, our ROAS in the first quarter of 2024 improved versus the first quarter of 2023. In general, for the year, we expect marketing will grow generally in line with sales. And in terms of pacing, what I would say is, we typically have more repeat in the back of the year than in the early part of the year, and as a result, that is sort of how the cadence of marketing spend across the year flows. I won’t comment by brand, but very big expectations for both brands this year. I expect a very strong performance, driven in part by the excellent execution on marketing, among other things.

Oran Holtzman: Sure. I will touch the cadence and then we’ll connect you to SpoiledChild. In Q1 2023, I did a mistake and grew too much. We grew 83%, which led to an insane growth of 57% for the full year and we decided not to do it again, although I strongly believe we could. The goal for the long-term is, again, as we mentioned before, 20% plus and 20% EBITDA margin and by pacing the growth, I’m ensuring it will happen and will continue to be in way. For Q1, we built the model and managed the growth to support 22% to 24% year-over-year, and I will say it again, pacing growth is my decision. But even when we are pacing the growth to 20% plus, we are going way more than my legacy competitors, which are in single digits and we are still securing the business early in the year, age one, it’s still the most important period for us. In 2023, 60% of our revenue was captured in age one, and in 2024, we expect age one to represent a very similar number to 60%. And with — but we don’t need to increase Q1 or the first half of the percentage of total in a year to do so. And as for SpoiledChild, I blitzscale SpoiledChild in 2023 to see what the brand potential was. It’s a new brand, you don’t know, like, what are the limits and we wanted to get more data. So I allowed the reason for the blitzscaling from all the 300% growth, it was purely my decision. So I let them grow. And no plan — no need to blitzscale again in 2024. So if you ask about the comparison between IL MAKIAGE and SpoiledChild, yes, it grew faster than IL MAKIAGE, because I allowed it to grow faster. Back then in IL MAKIAGE, early days, I limited their growth and — but that — for that reason, it was very consistent for $25 million revenue to $400 million, around $400 million of revenue this year. And the plan is to continue to do the same with SpoiledChild. So after blitzscaling now, we go back to a normal growth rate with a brand to make sure that everything is supporting their growth level.

Youssef Squali: Okay. Thank you both.

Operator: Our next question comes from the line of Andrew Boone with JMP Securities. Please proceed with your question.

Andrew Boone: Good morning. Thanks so much for taking my questions. International grew 13% year-over-year in 2023. This is below IL MAKIAGE’s total growth of 33%. Is there anything to call out there or is that one example of you guys holding back on growth initiatives? And then, Lindsay, stepping back, you guys have beaten the guidance by about $10 million each quarter. Is there something unique in 2023 or is there a way that we should be thinking about the conservatism that you’re setting out in the guide and how we set expectations for 2024? Thanks so much.

Oran Holtzman: Sure. I will start with international and then, Lindsay, you can refer to the guidance. We see a massive opportunity in international, as I said before, for other competitors. It is two-thirds of their business. But we have not finished growing in North America yet, either. We are building out very strong localized experience for each market we enter, which gives us strong and profitable performance from day one when we launch new markets and this is a big level for us and we want to continue to use it. Again, it’s my decision on how quickly we want to pace growth and prioritize it. Due to the fact that we are a fully direct consumer, I can decide at any given moment where I want to spend the next dollar, meaning under which brand, in which brand — and under which brand, against which category, product and geography. All is being measured daily and we allocate based on that. We have more than 10, I want to say more than 10 countries that are already tested that we know as a fact that we have very strong results, very strong unit economics, very strong scale and we pause to ensure that we have a significant runway ahead and that’s it. When we need those markets, we’re going to open them.

Lindsay Drucker Mann: Great. I’ll continue on the question about our guidance. You’re right, as a public company and every time we’ve spoken to you, we’ve over performed on every metric, achieved or mostly exceeded on every single metric that we committed to delivering. This is one of the favorite things about when I first met Oran, I’ve never missed a budget and I never planned to, and obviously, as a CFO and for us and our team, that’s really important in terms of building confidence with our investors that we do what we say we’re going to do and that’s 100% how we think about the business. We set out very, very big goals internally and we ensure everything possible that we achieve them. And then we also make sure that we’re delivering to our investors a framework that we know we can make good on and that’s why we have so much conviction in our guidance for 2024 and our long-term guidance, because on an underlying basis, if we wanted to, we could be delivering faster topline growth. We can see it. I mean, it’s very obvious just based on how the first quarter has come together that we could do nicely ahead of the numbers that we’re laying out for you today. We could also be a lot more profitable, but that’s not the right way for us to approach if we want many, many years of steady, durable compounding. As it relates to 2023, we did over-deliver by a pretty wide margin. Some of that is because we ramped so much in the first quarter and the first half of last year. We had a sort of a big wave of first orders that came in and we got a big wave of repeat in the back half of the year, and we always try to take a conservative approach to modeling, but we were overly conservative in modeling repeat, and so ultimately that, and repeat is quite profitable, so we ended up delivering ahead of plan. Our objective for 2024 and our second year as a public company, is to try to land the plane much more closely to our targets. And so, as you guys think about your models, number one, from a revenue perspective, we plan to land the plane much more in line with the guidance that we set out. In addition, every incremental dollar of revenue upside, we plan to reinvest in the business as I talked about in my prepared remarks. We think that’s the amazing use of our capital for future value creation.

Andrew Boone: Thank you.

Operator: Our next question comes from the line of Dara Mohsenian with Morgan Stanley. Please proceed with your question.

Dara Mohsenian: Hey, guys. Good morning. So we spent a lot of time on ODDITY LABS, but obviously you guys are very excited about it. Can you just give us an update on how much of a revenue driver you expect that to be along with vision technology in 2024 and just what’s embedded in the revenue guidance? And then as you think about the commercial development of the business over time, looking out beyond 2024, how important each of those areas might be conceptually? I know you probably won’t want to give us exact numbers, but how do you think about it looking out over the next few years, each of those areas?

Oran Holtzman: Yeah. I can start and maybe Evan or Lindsey, you can join me. Look, we can deliver the results or the guidance for this year without any product from ODDITY LABS. And we are — the teams are ready, the product is great, the market, everything’s ready to deliver everything without LABS. Having said that, we will go to test LABS, products from LABS, and it means that probably some of the revenue will come from [Technical Difficulty]

Dr. Evan Zhao: Yeah. Hi. I just wanted to reemphasize one point, which is all of the projects that LABS is working on, we think are very high impact. We have an amazing commercial team that works with the LAB crew to decide what projects we want to work on and we really only target the markets we think could be huge revenue drivers. So think about things that could replace entire sections of the business and so it gives you an idea of what we expect the impact we’re working on to be.

Dara Mohsenian: Great. And then can you touch on vision technology a bit? Sorry, my phone cut out for a second, but just cover how important that might be as you look out over the next few years?

Lindsay Drucker Mann: Great. I’ll take this one, because I think, Oran’s having trouble with his line. So vision technology is the capability that we established with the acquisition of Voyage81 in 2021. There are so many applications for this technology. We really have the team prioritizing two objectives. The first is to make our existing matching capabilities stronger and the second is to build really new diagnostic tools. As it relates to making our existing matching capabilities stronger, right now, for example, in our PowerMatch engine, we’re making product recommendations based on data alone, what the user tells us about themselves. But of course, there’s information that we can glean above and beyond that. Sometimes things that they don’t know about using vision. And so incorporating vision into PowerMatch was something that we really have been working on from the beginning. Last year, we had some more implementation. This year, we’re going to take it even further. We’re still in pretty early days as far as how much vision we can use for — to do better matching, but we’re already seeing the benefits for sure. And even though we’ve got 90% accuracy already in shade matching, every incremental 50 basis points, 100 basis points effectively flows through for us to the bottomline. So that’s already in process. You’re already seeing it in our products today. You’re already seeing it in our results for existing brands, but we expect more of that in the future. The next really big and transformational innovation for vision is how we implement it in Brand 3. And as Oran talked about it, with Brand 3, we’re really creating a first-of-its-kind mobile platform that will number one, support full diagnostics. So what are your skin issues and concerns, using machine models, data and AI and computer vision to do it. Number two, what’s the right treatment protocol, so what do you use to fix the issue? And again, using our machine learning models for those product recommendations. And then finally, coaching and upkeep, which will support compliance. So oftentimes, for example, with an issue like acne, your problem might get worse before it gets better and so that coaching component is really important for churn, and vision is, of course, an integral part in helping people understand how they’re progressing and their improvement. So those are three applications for Brand 3 and vision that we think are truly groundbreaking, and you’ll hear us talk a lot more about that when we launch Brand 3 and have it on the ground running.

Oran Holtzman: Guys, can you hear me?

Lindsay Drucker Mann: Yes.

Oran Holtzman: Yes. Cool. I would just add to that that we have around 30 people on the computer vision side and around 20 out of the 30 are working on Brand 3 for diagnosis and for the mobile application that we are building there, and the rest of the people are working for Brand 1, Brand 2, which is in my case, in SpoiledChild, and we already see results, better matching and better unit economics just based on the addition that we had with the computer vision.

Dara Mohsenian: Great. And then if I can slip one more in, you talked about managing the pace of revenue growth to a bit more manageable level this upcoming year versus 2023 when you’re obviously a very outsized growth. Can you just talk about sort of how you think about that conceptually in terms of what level of growth is healthy for the business from a topline standpoint and how that impacts the long-term revenue opportunity of the company and how you think about that relative to profitability?

Oran Holtzman: Yeah. So the way that we measure everything is based on contribution, meaning EBITDA level based on the brand and we don’t spend media dollars against products that we don’t see. Very strong results in terms of 12 months and 24 months direct contribution margin. So every dollar that you spend is more or less equal, otherwise you will spend against something else. In terms of visibility and managing the growth, again, last year was something unique, was the first year of full scale or full scale that I allowed for SpoiledChild. And again, it’s something that we didn’t have because we didn’t know the repeat numbers that we were going to see from this brand and the results were very, very strong. That’s the main reason for the additional dollars that we had against our guidance and we hope that we are modeling this now better. Again, it’s a good problem to have and — but the repeat rates are the main driver for the — for our business and it’s less about new acquisition, because in Q4, even in Q3 last year, we almost, like, we cut and spent way less than what we are going to spend. So it’s purely about repeat.

Dara Mohsenian: Great. Thank you.

Operator: Thank you. Our next question comes from the line of Lauren Lieberman with Barclays. Please proceed with your question.

Lauren Lieberman: Great. Thanks. Hey. Good morning. So I know in the prepared remarks and through the conversation since, you talked a lot about where you’re reinvesting and proactive reinvestment and then the incremental dollar goes back into reinvesting for future growth. But we have gotten asked by people prior to the call just about sort of cost of growth and thinking back, Lindsay, to your mention earlier of the high return model of a software business. So if we look out over, let’s call it, the next five years, maybe you guys tell me what the right time frame is. When should we think about that sort of high incremental returns business model being more apparent externally? Again, I understand the notion of investing for future growth, but just putting together the high return model and that being completely visible externally versus the continuing to invest for future growth.

Oran Holtzman: Yeah. I could just say that, look, we — even now for this year, if you ask me a few months back, I would say that, I want to guide for 20% EBITDA margin, but we thought that the business is very more profitable and there is a limit of how much we can invest in future initiatives this year, and therefore, we got it for around 22%. So the business is already, even with all the investments that we are doing, is already way more profitable and — but again, if you ask me what I want to do, I want to stick with this number. I want to continue to invest in the future. There is so much to be done. Again, there are two massive transformations in the industry that we see. One of them is online, which is technology. That’s all we need to continue to invest in our tech team to ensure that we are way ahead in terms of our competitors. And the second is ODDITY LAB. I believe that the opportunity there is massive. Adding to that Brand 3, Brand 4, every new brand that we launch, the first year or two, we need to invest. And therefore, as we continue to invest around tech, as we continue to invest around ODDITY LAB, as we continue to build more brands, this is the future of the company and this is why I’m still here. This is like, we are here to build something. Otherwise, I would sell the business. So the plan is 100% to continue to invest and there is no reason in my view to deliver more than 20%. The business is already generating so much cash. We have zero debt. And I don’t see a reason to deliver 30% of the margin.

Lauren Lieberman: Okay. Great.

Lindsay Drucker Mann: Let me just add, I’ll just add one thing, Lauren, to that.

Lauren Lieberman: Yeah. Go ahead.

Lindsay Drucker Mann: So as you think about, again, the returns on our business, one important differentiator versus any big duty or consumer conglomerate is our ability to build brands organically. And as I mentioned, we launched Spoiled with $20 million of upfront investment. Spoiled is over $100 million of net revenue. Today for us, if you were to apply a beauty M&A multiple of 5 times to 10 times revenue, you’d have to pay $500 million to $1 billion to acquire that. And so, without opining specifically on Spoiled, but just to kind of measure the return on capital for us, building brands organically versus a big legacy conglomerate, you can see there’s just this sort of step function change on the type of ROI you can deliver with our model as a land-and-expand type model, as we’re gaining a new share of existing wallets at very, very high incremental margins. So sort of at maturity, we believe our model lends itself to higher return profile versus the legacy model. That being said, we are a fraction of market share of a massive global market and there are so many ways for us to grow. I — we could be growing like this for many, many, many years before we’re even close to hitting a wall. So it’s really hard to say at any point in the forecast horizon, you’re going to see us actually deliver those types of returns, because we — the higher margin profile specifically, because we have so many ways to grow that just — I don’t see anywhere in the forecast horizon where we’re going to actually be delivering that because we have so many ways to invest for growth.

Oran Holtzman: I just want to add…

Lauren Lieberman: Okay.

Oran Holtzman: … one more thing…

Lauren Lieberman: Yeah.

Oran Holtzman: … regarding margins. When we launched SpoiledChild, although it was an amazing success, the first year, 2022, it had single-digit EBITDA margin and second year was already double-digit, but it was less than IL MAKIAGE. Now they’re running very strong EBITDA margin, but again, it takes time. So when we launch Band 3, for example, like it will be — it will cost us in terms of margins, and therefore, every brand that we launch, it damages short-term our margins, but long-term it supports high growth and with very healthy margin, otherwise we will not spend against it.

Lauren Lieberman: Okay. That’s really helpful. One more quick thing on Brand 3, on the acne. I think at one point you talked about having sort of a pharmacy element to this and now you’re saying medical grade. So I just wanted to check in on that. Is there still sort of an online or a pharmacy function that’s going to be part of this or is it medical grade, something different?

Oran Holtzman: Yeah. Yeah, it’s going to be both OTC and Rx, and we are not going to start with our own pharmacy, we’ll start with third-party, just because of the regulation, because we want to see what works and what doesn’t before we invest so much against it, but it’s going to be both.

Lauren Lieberman: Okay. And then when can we expect to hear more about Brand 4, just that we’re beginning of March 2024? Just curious how to think about when you’ll give us an update on what category or anything more specific about what Brand 4 will look like?

Oran Holtzman: First I need to tell my team, my team don’t know yet. But, again, there is a reason why we are working on those things quietly and three brands now, Brand 4 is in the making, both my sister and I are involved, there is already a team there and once we have something to share, we will.

Lauren Lieberman: Okay. Sounds good. Thank you.

Operator: Thank you. There are no further questions at this time. I would like to turn the floor back over to Oran Holtzman for closing comments.

Oran Holtzman: Thank you very much guys for joining. We’ll talk with you when we report the first quarter. Have a great day. Bye-bye.

Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.